Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
Modulation of Insulin Resistance in NAFLD.
R Khan, F Bril, K Cusi,
PN Newsome
Nursing and Midwifery
Immunology and Immunotherapy
Research output
:
Contribution to journal
›
Article
›
peer-review
79
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Modulation of Insulin Resistance in NAFLD.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Insulin Resistance
100%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Nonalcoholic Steatohepatitis
37%
Patients with Diabetes
12%
Disease Progression
12%
Cardiovascular Risk
12%
Novel Treatments
12%
Liver Transplantation
12%
Close Relationships
12%
A1 Receptor
12%
Prevalence Estimation
12%
Clinical Data
12%
Steatosis
12%
Cirrhosis
12%
Pharmacological Strategies
12%
Receptor Agonist
12%
Fat Distribution
12%
Biguanides
12%
Disease Treatment
12%
Combinatorial Approach
12%
Dipeptidyl peptidase-4 (DPP-4)
12%
Glucagon-like
12%
Adipokines
12%
Gut Microbiome
12%
Peroxisome Proliferator-activated Receptor Agonists
12%
Farnesoid X Receptor
12%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
12%
Adipocyte Lipolysis
12%
De-novo Lipogenesis
12%
Mitochondrial Fatty Acid Oxidation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Insulin Resistance
100%
Nonalcoholic Fatty Liver
100%
Prevalence
18%
Cytokine
9%
Combination Therapy
9%
Disease Exacerbation
9%
Cardiovascular Risk
9%
Receptor Agonist
9%
Fatty Acid
9%
Liver Cirrhosis
9%
Steatosis
9%
Adipocytokine
9%
Dipeptidyl Peptidase IV Inhibitor
9%
Glucagon Like Peptide 1 Receptor Agonist
9%
PPAR Agonist
9%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Microbiome
9%
Biguanide Derivative
9%
Farnesoid X Receptor
9%